VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Bart Claes(VIB-KU Leuven Center for Cancer Biology), Paul Delmar(Roche (Switzerland)), Joke Reumers(VIB-KU Leuven Center for Cancer Biology), Massimiliano Mazzone(VIB-KU Leuven Center for Cancer Biology), Betül T. Yesilyurt(VIB-KU Leuven Center for Cancer Biology), Roland Devlieger(Universitair Ziekenhuis Leuven), Chris Verslype(Universitair Ziekenhuis Leuven), Sabine Tejpar, Hans Wildiers, Sanne de Haas(Roche (Switzerland)), Peter Carmeliet(VIB-KU Leuven Center for Cancer Biology), Stefan Scherer(Roche (Switzerland)), Eric Van Cutsem
Cited by 187
Abstract
Related Papers
No related papers found
Powered by citation graph analysis